Ashfield Launches EmerGENE

New cell and gene therapy commercialization network set to support small and midsize biotechs.

Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.

EmerGENE will provide guidance on all areas, including commercialization strategic support, early clinical development guidance, distribution and logistics, market access and patient and HCP engagement and support.

Read more about the network's launch here.